The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“In addition, signaling resulting from interactions between epithelial cells and stroma also contributes to tumor development (Bhowmick and Moses, 2005; Bissell and Radisky, 2001; Kalluri and Zeisberg, 2006; Red-Horse et al., 2007).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 2×
“Other studies investigating tumor resistance/refractoriness to antiangiogenic therapies with VEGF blockers have identified additional potential mechanisms, including expression of alternative angiogenic factors (Bergers and Hanahan, 2008; Fischer et al., 2007), selection of hypoxia-resistant tumor cells (Yu et al.”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationRole of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Cited by
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
“PDGF-CC, another family member released by cancer-associated fibroblasts in VEGF-inhibitor-resistant tumours, stimulates vessel growth and maturation, and attenuates the response to anti-VEGF treatmen”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
“Similar evidence in the field of anti-angiogenic therapies implicates the stroma in resistance to therapy through release of PDGF-C by cancer-associated fibroblasts (CAFs) (Crawford et al., 2009).”
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
“Such responses include hypoxia-mediated induction of other proangiogenic factors, such as Ang1 and FGFs,(42,43) or upregulation of PDGF-C expression in tumor-associated fibroblasts.(44) Furthermore, TIE2-expressing monocytes (TEMs) appear to play an important role in tumor angiogenesis by secreting proangiogenic signa…”
BackgroundHallmarks of cancer: Interactions with the tumor stroma
Pietras, K., & Östman, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.045 · Cited by 1,141
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
Zhang, H., Deng, T., Liu, R., Ning, T., Yang, H., Liu, D., Zhang, Q., Lin, D., Ge, S., Bai, M., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01168-8 · Cited by 1,016
Langley, R. R., & Fidler, I. J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26031 · Cited by 958
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 771
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Self-citationAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Developmental and Pathological Angiogenesis
Chung, A. S., & Ferrara, N. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154002 · Cited by 722
Self-citationAntiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Chemokines and chemokine receptors: new insights into cancer-related inflammation
Lazennec, G., & Richmond, A. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.003 · Cited by 650
The angiogenic switch in carcinogenesis
Baeriswyl, V., & Christofori, G. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.05.003 · Cited by 625
Chu, T., Wang, Z., Pe’er, D., & Danko, C. G. (2022) · Nature Cancer · doi:10.1038/s43018-022-00356-3 · Cited by 603
Cancer-associated fibroblasts in gastrointestinal cancer
Kobayashi, H., Enomoto, A., Woods, S. L., Burt, A. D., Takahashi, M., & Worthley, D. L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0115-0 · Cited by 589
Luo, H., Xia, X., Huang, L.-B., An, H., Cao, M., Kim, G. D., Chen, H.-N., Zhang, W.-H., Shu, Y., Kong, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34395-2 · Cited by 567
Cancer-associated fibroblasts and tumor growth – bystanders turning into key players
Östman, A., & Augsten, M. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.01.003 · Cited by 543
Targeting the PDGF signaling pathway in tumor treatment
Heldin, C.-H. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-97 · Cited by 540
Adipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
Makhov, P., Joshi, S., Ghatalia, P., Kutikov, A., Uzzo, R. G., & Kolenko, V. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1299 · Cited by 521
Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
Cirri, P., & Chiarugi, P. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9340-x · Cited by 519
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Self-citationShojaei, F., Wu, X., Qu, X., Kowanetz, M., Yu, L., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902280106 · Cited by 471
Self-citationBroad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Epithelial stem cells, wound healing and cancer
Arwert, E. N., Hoste, E., & Watt, F. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3217 · Cited by 449
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy
Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.-M., Jiang, Z., Meng, Y. G., Peale, F. V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3291 · Cited by 445
Self-citationLiao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
“Furthermore, there have been unexpected consequences of VEGF inhibition including an up-regulation of compensatory angiogenic pathways (Crawford et al. 2009) and increased metastasis in some mouse tumor models (Ebos et al.”
BackgroundCell-cell communication: New insights and clinical implications
Su, J., Song, Y., Zhu, Z., Huang, X., Fan, J., Qiao, J., & Mao, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01888-z · Cited by 433
Anti-angiogenic therapy: current challenges and future perspectives
Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073765 · Cited by 416
Pericyte–fibroblast transition promotes tumor growth and metastasis
Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E., Hartman, J., Religa, P., Morikawa, H., Ishii, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608384113 · Cited by 415
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Navab, R., Strumpf, D., Bandarchi, B., Zhu, C.-Q., Pintilie, M., Ramnarine, V. R., Ibrahimov, E., Radulovich, N., Leung, L., Barczyk, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014506108 · Cited by 364
‘Cancer associated fibroblasts’ – more than meets the eye
Madar, S., Goldstein, I., & Rotter, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.004 · Cited by 362
Lotti, F., Jarrar, A. M., Pai, R. K., Hitomi, M., Lathia, J., Mace, A., Gantt, G. A., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 359
Anti-angiogenesis therapy in cancer: Current challenges and future perspectives
Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 346
Targeting the Tumor Microenvironment for Cancer Therapy
Sounni, N. E., & Noel, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.185363 · Cited by 344
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
Markers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332
Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C., Tai, Y., Zhang, Q., & Chen, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.020 · Cited by 328
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression
Shimoda, M., Mellody, K. T., & Orimo, A. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.10.002 · Cited by 325
Modi, S. J., & Kulkarni, V. M. (2019) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2019.100009 · Cited by 320
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319
Pathways mediating VEGF-independent tumor angiogenesis
Ferrara, N. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.003 · Cited by 313
Self-citationRaica, M., & Cimpean, A. M. (2010) · Pharmaceuticals · doi:10.3390/ph3030572 · Cited by 304
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance
Iwamoto, H., Abe, M., Yang, Y., Cui, D., Seki, T., Nakamura, M., Hosaka, K., Lim, S., Wu, J., He, X., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.005 · Cited by 300
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Ebos, J. M. L., Lee, C. R., & Kerbel, R. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0095 · Cited by 291
Fibroblast activation in cancer: when seed fertilizes soil
Kuzet, S.-E., & Gaggioli, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2467-x · Cited by 290
Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands
Cao, Y. (2009) · Science Signaling · doi:10.1126/scisignal.259re1 · Cited by 289
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
Fang, Z., Meng, Q., Xu, J., Wang, W., Zhang, B., Liu, J., Liang, C., Hua, J., Zhao, Y., Yu, X., et al. (2023) · Cancer Communications · doi:10.1002/cac2.12392 · Cited by 280
Microenvironment and tumor cell plasticity: An easy way out
Taddei, M. L., Giannoni, E., Comito, G., & Chiarugi, P. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.042 · Cited by 264
Fibroblasts as architects of cancer pathogenesis
Marsh, T., Pietras, K., & McAllister, S. S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.10.013 · Cited by 264
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W., Linton, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 259
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Cao, Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.002 · Cited by 190
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Cancer-associated fibroblasts promote angiogenesis in gastric cancer through galectin-1 expression
Tang, D., Gao, J., Wang, S., Ye, N., Chong, Y., Huang, Y., Wang, J., Li, B., Yin, W., & Wang, D. (2016) · Tumor Biology · doi:10.1007/s13277-015-3942-9 · Cited by 138
“leukin-8, and combined with other proangiogenic growth factors in the tumor, myofibroblast-derived proangiogenic factors can coordinate the angiogenic balance in favor of tumor angiogenesis [1, 45, 47, 48].”
BackgroundWang, F., Sun, W., Zhang, J., & Fan, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9973 · Cited by 115
Determinants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“Likewise, CAFs derived from anti-VEGF-resistant tumors are secreting PDGF-C in order to reactivate tumor angiogenesis (Crawford et al., 2009).”
BackgroundPDGFRα plays a crucial role in connective tissue remodeling
Horikawa, S., Ishii, Y., Hamashima, T., Yamamoto, S., Mori, H., Fujimori, T., Shen, J., Inoue, R., Nishizono, H., Itoh, H., et al. (2015) · Scientific Reports · doi:10.1038/srep17948 · Cited by 98
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Co-migration of colon cancer cells and CAFs induced by TGFβ₁ enhances liver metastasis
Gonzalez-Zubeldia, I., Dotor, J., Redrado, M., Bleau, A.-M., Manrique, I., de Aberasturi, A. L., Villalba, M., & Calvo, A. (2015) · Cell and Tissue Research · doi:10.1007/s00441-014-2075-6 · Cited by 51
Regulation of Transforming Growth Factor-β-dependent Cyclooxygenase-2 Expression in Fibroblasts
Matsumura, T., Suzuki, T., Aizawa, K., Sawaki, D., Munemasa, Y., Ishida, J., & Nagai, R. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014639 · Cited by 28
Metadata
- Authors
- Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 15
- Issue
- 1
- Pages
- 21-34
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2103928688
- Cited by
- 611
- References
- 54
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.